JP2016513647A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016513647A5 JP2016513647A5 JP2016502054A JP2016502054A JP2016513647A5 JP 2016513647 A5 JP2016513647 A5 JP 2016513647A5 JP 2016502054 A JP2016502054 A JP 2016502054A JP 2016502054 A JP2016502054 A JP 2016502054A JP 2016513647 A5 JP2016513647 A5 JP 2016513647A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- bimatoprost
- administered
- composition according
- reducing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 18
- AQOKCDNYWBIDND-FTOWTWDKSA-N Bimatoprost Chemical compound CCNC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)CCC1=CC=CC=C1 AQOKCDNYWBIDND-FTOWTWDKSA-N 0.000 claims 12
- 229960002470 bimatoprost Drugs 0.000 claims 12
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N Leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 claims 3
- 102000016267 Leptin Human genes 0.000 claims 3
- 108010092277 Leptin Proteins 0.000 claims 3
- 230000002708 enhancing Effects 0.000 claims 3
- 229940039781 leptin Drugs 0.000 claims 3
- 206010012601 Diabetes mellitus Diseases 0.000 claims 2
- 208000008338 Non-alcoholic Fatty Liver Disease Diseases 0.000 claims 2
- 210000000229 preadipocyte Anatomy 0.000 claims 2
- 210000000577 Adipose Tissue Anatomy 0.000 claims 1
- 206010022490 Insulin resistance syndrome Diseases 0.000 claims 1
- 208000008466 Metabolic Disease Diseases 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 230000036528 appetite Effects 0.000 claims 1
- 235000019789 appetite Nutrition 0.000 claims 1
- 230000004069 differentiation Effects 0.000 claims 1
- 201000010870 diseases of metabolism Diseases 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 229940002612 prodrugs Drugs 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 230000001629 suppression Effects 0.000 claims 1
- 230000000699 topical Effects 0.000 claims 1
- 230000004580 weight loss Effects 0.000 claims 1
Claims (18)
- ビマトプロストを有効成分として含む、ヒトにおけるレプチンレベルの増進用組成物。
- 前記ビマトプロストが、全身投与される、請求項1に記載の組成物。
- 前記ビマトプロストが、局所投与される、請求項1に記載の組成物。
- 前記ビマトプロストが、脂肪組織におけるレプチン生産を増進させる、請求項3に記載の組成物。
- プレ脂肪細胞におけるレプチン生産を増進させる、請求項3に記載の組成物。
- ヒトの食欲を抑制するための、請求項1に記載の組成物。
- II型糖尿病を処置するための、請求項3に記載の組成物。
- 代謝性疾患、II型糖尿病、インシュリン耐性症候群、代謝症候群及び非アルコール性脂肪肝からなる群から選択される症状を処置するための、請求項3に記載の組成物。
- 体重低下をもたらすための、請求項1に記載の組成物。
- 前記ビマトプロストが経皮パッチによって投与される、請求項3に記載の組成物。
- 前記ビマトプロストが皮下投与される、請求項2に記載の組成物。
- 肥満を処置するための請求項1に記載の組成物。
- 前記ビマトプロストが、ビマトプロストのプロドラッグである、請求項1に記載の組成物。
- プレ脂肪細胞の分化を低減し、または抑制する、請求項1に記載の組成物。
- 前記ビマトプロストの局所適用または皮下適用により、適用部位及び該適用部位の遠位にて脂肪を低減するための、請求項1に記載の組成物。
- 非アルコール性脂肪肝の開始を防止し、かつ軽減するための、請求項1に記載の組成物。
- 前記ビマトプロストの濃度が、0.1w/w%、0.3w/w%、1w/w%、2w/w%及び3w/w%のビマトプロストからなる1つから選択される、請求項1に記載の組成物。
- 前記ビマトプロストが、経皮パッチで患者に投与される、請求項1に記載の組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361793132P | 2013-03-15 | 2013-03-15 | |
US61/793,132 | 2013-03-15 | ||
PCT/US2014/026110 WO2014143629A1 (en) | 2013-03-15 | 2014-03-13 | Bimatoprost for enhancement of leptin production |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2016513647A JP2016513647A (ja) | 2016-05-16 |
JP2016513647A5 true JP2016513647A5 (ja) | 2017-04-13 |
Family
ID=50442712
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016502054A Pending JP2016513647A (ja) | 2013-03-15 | 2014-03-13 | レプチン生産を増進するビマトプロスト |
Country Status (11)
Country | Link |
---|---|
US (2) | US20140275272A1 (ja) |
EP (1) | EP2968361A1 (ja) |
JP (1) | JP2016513647A (ja) |
KR (1) | KR20150129735A (ja) |
CN (1) | CN105338985A (ja) |
AU (1) | AU2014228307A1 (ja) |
BR (1) | BR112015021859A2 (ja) |
CA (1) | CA2901529A1 (ja) |
HK (1) | HK1220385A1 (ja) |
RU (1) | RU2015134772A (ja) |
WO (1) | WO2014143629A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2017013819A (es) | 2015-04-30 | 2018-02-21 | Allergan Inc | Metodos para la reduccion de grasa. |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4911920A (en) | 1986-07-30 | 1990-03-27 | Alcon Laboratories, Inc. | Sustained release, comfort formulation for glaucoma therapy |
FR2588189B1 (fr) | 1985-10-03 | 1988-12-02 | Merck Sharp & Dohme | Composition pharmaceutique de type a transition de phase liquide-gel |
ATE141502T1 (de) | 1991-01-15 | 1996-09-15 | Alcon Lab Inc | Verwendung von karrageenan in topischen ophthalmologischen zusammensetzungen |
US5212162A (en) | 1991-03-27 | 1993-05-18 | Alcon Laboratories, Inc. | Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions |
US5688819A (en) | 1992-09-21 | 1997-11-18 | Allergan | Cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents |
US6309853B1 (en) | 1994-08-17 | 2001-10-30 | The Rockfeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
CA2681668C (en) * | 2006-03-23 | 2014-04-01 | Michael S. Singer | Compositions comprising prostaglandin f2-alpha analogs and methods for reducing body fat |
EP2398443A2 (en) * | 2009-02-20 | 2011-12-28 | Micro Labs Limited | Storage stable prostaglandin product |
EP3378480A1 (en) * | 2011-01-19 | 2018-09-26 | Topokine Therapeutics, Inc. | Methods and compositions for treating obesity |
-
2014
- 2014-03-13 CN CN201480012846.5A patent/CN105338985A/zh active Pending
- 2014-03-13 JP JP2016502054A patent/JP2016513647A/ja active Pending
- 2014-03-13 CA CA2901529A patent/CA2901529A1/en not_active Abandoned
- 2014-03-13 AU AU2014228307A patent/AU2014228307A1/en not_active Abandoned
- 2014-03-13 KR KR1020157025059A patent/KR20150129735A/ko not_active Application Discontinuation
- 2014-03-13 RU RU2015134772A patent/RU2015134772A/ru not_active Application Discontinuation
- 2014-03-13 US US14/209,099 patent/US20140275272A1/en not_active Abandoned
- 2014-03-13 WO PCT/US2014/026110 patent/WO2014143629A1/en active Application Filing
- 2014-03-13 BR BR112015021859A patent/BR112015021859A2/pt active Search and Examination
- 2014-03-13 EP EP14716168.1A patent/EP2968361A1/en not_active Withdrawn
-
2015
- 2015-11-25 US US14/952,208 patent/US20160310505A1/en not_active Abandoned
-
2016
- 2016-07-19 HK HK16108521.3A patent/HK1220385A1/zh unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2020012595A (es) | Composiciones farmaceuticas topicas. | |
JP2014505733A5 (ja) | ||
BR112014010275A2 (pt) | formulações para tratamento de diabetes | |
NZ757815A (en) | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity | |
JP2012532093A5 (ja) | ||
WO2015085143A3 (en) | Therapeutic agents for skin diseases and conditions | |
RU2013141845A (ru) | Фармацевтическая композиция в виде крема, содержащая оксиметазолин, для лечения симптомов розацеа | |
FR3024037B1 (fr) | Ingredient actif cosmetique ou dermatologique comprenant un melange d'acides dicarboxyliques gras insatures, compositions le comprenant et utilisations cosmetiques ou dermatologiques | |
WO2014107730A3 (en) | Use of fatty acid niacin conjugates for treating diseases | |
JP2017503798A5 (ja) | ||
WO2015095354A3 (en) | Compositions and methods for treating fatty tissue buildup | |
EP4219714A3 (en) | Rna interference mediated inhibition of tmprss6 | |
ATE522224T1 (de) | Medizinisches kräuterextrakt mit wirkung gegen adipositas | |
CO7170176A2 (es) | Nuevo compuesto que tiene la capacidad para inhibir la enzima deshidrogenasa11b-hidroxiesteroide tipo 1(11b-hsd1) o sal farmaceúticamente aceptable del mismo, método para producir el mismo, y composición farmaceútica que contiene el mismo como ingrediente activo | |
WO2011147536A3 (en) | Topical pharmaceutical compositions comprising mometasone furoate | |
WO2015121457A8 (en) | Fgf-8 for use in treating diseases or disorders of energy homeostasis | |
WO2018093237A3 (ko) | 포름산 또는 이의 약학적으로 허용가능한 염을 유효성분으로 포함하는 비만 또는 비만으로 야기된 대사증후군의 예방 또는 치료용 조성물 | |
JP2016513647A5 (ja) | ||
JP2019529569A5 (ja) | ||
JP2018536638A5 (ja) | ||
JP2014530223A5 (ja) | ||
MX2018013477A (es) | Acidos carboxilicos para tratar/prevenir una enfermedad de la piel. | |
JP2015517534A5 (ja) | ||
RU2015134772A (ru) | Применение биматопроста для повышения выработки лептина | |
EA201590825A1 (ru) | Способы контролирования кровяного давления и снижения диспноэ при сердечной недостаточности |